Long Covid presents challenges requiring a shift from symptom-based to immunological approaches, focusing on immune dysregulation and incomplete recovery. Monoclonal antibodies are explored for potential treatment, although evidence is inconsistent, highlighting the need for biomarkers for effective patient selection. Research remains essential for understanding Long Covid's complex biology.
Long Covid Journey 